Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma

Rutvij A. Khanolkar<sup>a</sup>, Harvey Quon<sup>a,b</sup>, Kundan Thind<sup>a,b</sup>, Michael Sia<sup>a,b</sup>, Michael Roumeliotis<sup>a,b</sup>, Siraj Husain<sup>a</sup>, Philip McGeachy<sup>a,b</sup>, Tyler Meyer<sup>a,b</sup>, Kevin Martell<sup>a,b,*</sup>

<sup>a</sup> Department of Oncology, University of Calgary, Calgary, AB, Canada
<sup>b</sup> Alberta Health Services, Calgary, AB, Canada

**ARTICLE INFO**

**Keywords:** Prostate cancer, Brachytherapy, Wait times for treatment, Recurrence, Metastases

**ABSTRACT**

**Purpose:** It has previously been shown that increased wait times for prostatectomy are associated with poorer outcomes in intermediate-risk prostatic carcinoma (PCa). However, the impact of wait times on PCa outcomes following low-dose-rate brachytherapy (LDR-BT) are unknown.

**Methods and Materials:** We retrospectively reviewed 466 intermediate-risk PCa patients that underwent LDR-BT at a single comprehensive cancer center between 2003 and 2016. Wait times were defined as the time from biopsy to LDR-BT. The association of wait times with outcomes was evaluated using Cox and Fine-Gray regression in both univariate and multivariate models.

**Results:** Median (interquartile range) follow-up and wait time for all patients were 8.1 (6.3–10.4) years and 5.1 (3.9–6.9) months, respectively. Among NCCN unfavourable intermediate-risk (UIR) patients (n = 170; 36%), increased wait times predicted both a greater cumulative incidence of recurrence [MHR = 1.01/month of wait time (95% CI: 1.00–1.03); P < 0.001] and metastases [MHR = 1.04/month of wait time (95% CI: 1.02–1.06); P < 0.001] in multivariate modeling. In NCCN favourable intermediate-risk (FIR) patients, there was no significant association between wait time and recurrence or metastases risk. Among all intermediate-risk patients, wait time was associated with an increase in the incidence of metastases [MHR = 1.03/month of wait time (95% CI: 1.02–1.05); P < 0.001], but not recurrence in multivariate models. There was no association between wait time and overall survival in the UIR, FIR, or all intermediate-risk cohorts.

**Conclusions:** Resource constraints within this center’s public healthcare system have contributed to waitlists exceeding 5-months in length. This study finds that patients with UIR PCa experience a 1% increase in the risk of recurrence and 4% increase in the risk of metastases with each additional month of delay in definitive disease management. Preventing such extended management delays in LDR-BT may improve disease-related outcomes in patients with PCa.

---

1. Introduction

Prostate cancer (PCa) is one of the most commonly diagnosed malignant neoplasms in North America [1,2]. The number of patients requiring treatment, and hence the overall economic burden of prostate cancer, is expected to increase over the next decade [3–6]. This is important in resource constrained environments such as the Canadian health care system where an increased incidence of disease often leads to prolonged waitlists for treatment while infrastructure and resources are implemented.

These increased wait times could become a source of anxiety for patients and may also affect patient outcomes. For example, a previous study found that management delays in prostatectomy for intermediate-risk PCa were associated with worse recurrence-free survival and increased biochemical recurrence [7]. A similar, more recent study showed that longer wait times were associated with an increase in the UCSF-CARPA score, which have been previously been shown to be predict the risk of biochemical recurrence [8,9]. Although some studies

---

<sup>a</sup> Corresponding author at: Department of Oncology, University of Calgary, 1331-29 Street NW, Calgary, Alberta T2N 4N2, Canada. E-mail address: kevin.martell@albertahealthservices.ca (K. Martell).

https://doi.org/10.1016/j.ctro.2021.06.008
Received 17 June 2021; Accepted 27 June 2021
Available online 1 July 2021
2405-6308/© 2021 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC
suggest short delays to treatment are safe, several other international studies have also found that delays in surgical treatment for PCa predict poorer outcomes in patients [10–12].

Unfortunately, the potential for impact of wait times to radiotherapy treatments for prostate cancer has not been explored as of yet. On review, this is likely due to most radiotherapy treatments being less dependent on hospital resources such as operating room staffing. At this tertiary study center, however, patients enrolled for treatment with low-dose-rate brachytherapy (LDR-BT) for intermediate-risk PCa are routinely impacted by dependencies on hospital resources and variable procedural wait times ranging from 2 to 8 months. The current study aimed to evaluate whether these extremes of wait times for LDR-BT were associated with worse outcomes for patients with intermediate-risk PCa.

2. Materials and methods

2.1. Study design & data collection

The electronic medical records for all patients with PCa who received LDR-BT monotherapy at the Tom Baker Cancer Centre in Calgary, Alberta, Canada between 2003 and 2016, were retrospectively reviewed for this study. Data was accessed through centralized provincial electronic health records and electronic medical records systems which house all hospital visitations, diagnostic imaging, pathology, oncology consultation and follow-up and laboratory reports within the jurisdiction. Ethics approval for this study was obtained from the Health Research Ethics Board of Alberta (HREBA).

Predefined inclusion criteria for the current study consisted of patients with NCCN favorable or unfavorable intermediate-risk PCa that were treated with LDR-BT [13]. In brief, all patients had prostate specific antigen (PSA) between 10 and 20 and/or T2c disease and/or Gleason Grade Group 2 or 3 disease and no high risk features [14]. All patients were diagnosed based on trans-rectal ultrasound guided biopsy and all pathology underwent central review by dedicated genitourinary pathologists.

3. Treatment characteristics

Prior to LDR-BT, patients underwent gland size assessment on TRUS and CT and patients with gland sizes >50 cc received at minimum 3 months of neoadjuvant androgen deprivation therapy with subcutaneous leuprolide for gland volume reduction. LDR-BT plans were created using the Nuclertron SPOT® system (Elekta Inc, Stockholm, Sweden) and all patients were treating using an intraoperatively planned workflow described elsewhere [15]. A 3–5 mm margin was the primary clinical target volume for the prostate gland. Organs at risk including the rectum and urethra were routinely contoured. Institutional dose constraints were: prescribed dose: 144 Gy; D90 prostate > 180 Gy; CTV V100 > 98%; CTV V150 > 70%; CTV V200 > 40%; urethra V140 < 25%; Rectum V100 < 0.3 cc). Inverse planning was used to generate preliminary plans and manual modifications to seed placements within the plan were employed to ensure coverage of biopsy proven disease. Seed activities were 0.346 mCi for glands with volumes < 30 cc and 0.437 mCi for gland volumes > 30 cc.

4. Follow-up

Post treatment, patients underwent CT imaging at 1 month to confirm seed placement within the gland. Dosimetry was not routinely calculated at that time and no action ever taken based on undercoverage of any region of the prostate. Patients were instead followed with PSA measurements every 6–12 months for 5 years and then discharged to their family physician with recommendations of yearly PSAs thereafter for life. Patients experiencing recurrent disease were routinely offered hormonal therapy. A small number of young and healthy patients undergoing recurrence received salvage LDR-BT [16].

5. Statistical methods

Descriptive statistics were used to describe the cohort. The wait time was calculated as the time from biopsy to LDR-BT procedure. For non-normally distributed continuous variables, medians and inter-quartile-range were used. For binomial and ordinal variables, the absolute numeric count and proportion (percentage) were used. For comparisons of clinical factors between patient favorable and unfavorable intermediate-risk cohorts, GraphPad Prism software (version 5.02 for Windows, GraphPad software, San Diego, California, USA) was used. For the cumulative incidence of recurrence (CIR), time to event was defined as time from date of LDR-BT to date of last measured PSA value or recurrent disease on subsequent imaging analysis or biochemical failure (BF) as defined by the Phoenix definition [17]. For the cumulative incidence of metastases (CIM), the time to event was defined as the time from date of LDR-BT to date of metastases on imaging, censured to last medical contact. For OS, the time to event was defined as the time from PCa diagnosis (via biopsy) to death, censured to last medical contact.

Outcomes were analyzed in both univariate models (univariate hazard ratio; UHR) and multivariable models (multivariate hazard ratio; MHR). Univariable modeling included wait time as the sole variable. Multivariable cox proportional sub-distribution hazards models were created for two outcomes: cumulative incidence of recurrence (CIR) and cumulative incidence of metastases (CIM) with competing risks accounted for using Fine and Gray’s method [18]. To determine appropriate covariates to include in multivariate modeling, all variables of interest were analyzed in univariate analyses for P < 0.10 association with the outcomes of interest (Supplemental Table 1). For CIR and CIM, this included patient age (continuous) and the use of androgen deprivation therapy (ADT; yes vs. no). For OS, this included only patient age (continuous), however, ADT use (yes vs. no) was also included as a covariate since this controlled for differences in wait time that occurred due to the use of ADT (which would be an appropriate cause of management delay). Additionally, NCCN risk-group (favourable vs. unfavourable intermediate) was used as a covariate in the analysis of all outcomes when considering all treated patients despite not reaching statistical significance as this is a well-established prognostic factor for outcomes [13] and is a composite variable that controls for differences in measured characteristics listed in Table 1. Non-relapse death was used as a competing risk for CIR and CIM. Two-tailed P-values of < 0.05 were considered statistically significant. All regression analyses were performed using the R programming language version 4.0.0 (www.r-project.org).

6. Results

Four-hundred and sixty-six (466) consecutive patients with a median follow-up of 8.1 years (IQR: 6.3–10.4) met this study’s predefined inclusion criteria. The median wait time for all patients was 5.1 months (IQR: 3.9–6.9). Patient characteristics are displayed in Table 1. Among total patients, the median age at PCa diagnosis was 65.1 years (IQR: 59.8–69.3). 296 (64%) and 170 (36%) patients had favourable and unfavourable intermediate-risk disease, respectively. Dosimetry at the time of LDR-BT is given in Table 2. Median gland volume was 34.3 cc (IQR: 28.3–41.4). Median D90 at time of implantation was 189.9 Gy (IQR: 184.9–193.6) and median CTV V100 was 98.6% (IQR: 97.8–99.3).

Fig. 1 shows the CIR for the cohort. The estimated cumulative incidence of recurrence at 60 and 120 months were 10.8% (95% CI: 10.7–10.8) and 24.0% (IQR: 23.9–24.1), respectively. Amongst all patients, increased wait times for LDR-BT were found to be associated with an increased cumulative incidence of recurrence (CIR) in univariate, but not multivariable models. In univariate modeling, there was a 3% increase in the CIR per month of delay in LDR-BT (UHR = 1.03 (95% CI: 1.01–1.04); p < 0.001) (Supplemental Table 1). In multivariate modeling, there was a trend towards a significant difference in CIR based on wait times (MHR = 1.01 (95% CI: 1.00–1.03); p = 0.080).
Table 1
Baseline patient characteristics for the entire cohort and for those with favorable (FIR) and unfavorable (UIR) intermediate-risk prostate cancer. Values given are number (%) or median (inter-quartile-range) as appropriate.

|                      | All Patients | FIR PCa N = 466 | UIR PCa N = 170 | p-value |
|----------------------|--------------|------------------|-----------------|---------|
| Age at Biopsy [years]| 65.1 (59.8–69.3) | 64.3 (59.4–69.0) | 66.2 (60.4–69.9) | 0.039   |
| Initial PSA [ng/ml.] | 7.1 (5.4–9.2)  | 6.8 (5.3–8.8)    | 7.5 (5.5–10.0)  | 0.024   |
| Wait Time [months]   | 5.1 (3.9–6.9)  | 5.0 (198)         | 5.1 (114–215)   | 0.765   |
| Baseline AUA Score   | 6 (3–11)      | 6 (3–10)         | 6 (3–12)        | 0.561   |
| Clinical Stage       |               |                  |                 |         |
| T1a                  | 1 (0.2%)      | 1 (0.3%)         | 0 (0%)          | p < 0.001 |
| T1b                  | 0 (0%)        | 0 (0%)           | 0 (0%)          |         |
| T1c                  | 340 (73%)     | 224 (76%)        | 117 (68%)       |         |
| T2a                  | 88 (19%)      | 54 (18%)         | 34 (20%)        |         |
| T2b                  | 28 (6%)       | 12 (4%)          | 16 (9%)         |         |
| T2c                  | 9 (2%)        | 5 (2%)           | 4 (2%)          |         |
| Grade Group          |               |                  |                 |         |
| 1                    | 78 (17%)      | 61 (21%)         | 17 (10%)        |         |
| 2                    | 332 (71%)     | 235 (79%)        | 97 (57%)        |         |
| 3                    | 56 (12%)      | 0 (0%)           | 56 (33%)        |         |
| Biopsy Cores Sampled| 11 (10–12)    | 11 (10–12)       | 11 (10–12)      | p = 0.901 |
| Biopsy Cores Positive| 4 (2–6)    | 3 (2–4)          | 6 (3–7)         | P < 0.001 |
| Biopsy % positive    | 8.3 (4.4–14.0)| 7.0 (3.4–12.0)   | 11.0 (7.0–20.0) | 0.001   |
| Perineural invasion  |               |                  |                 |         |
| Yes                  | 132 (31%)     | 80 (27%)         | 63 (37%)        | p < 0.065 |
| No                   | 251 (54%)     | 170 (57%)        | 81 (48%)        |         |
| Unknown              | 72 (15%)      | 46 (16%)         | 26 (15%)        |         |
| Extraprostatic invasion| 0 (0%)    | 0 (0%)           | 0 (0%)          | p = 1.000 |
| Yes                  | 394 (85%)     | 250 (84%)        | 144 (85%)       |         |
| No                   | 72 (15%)      | 46 (16%)         | 26 (15%)        |         |
| Seminal vesicle invasion| 0 (0%)   | 0 (0%)           | 0 (0%)          | p = 1.000 |
| Yes                  | 394 (85%)     | 250 (84%)        | 144 (85%)       |         |
| No                   | 72 (15%)      | 46 (16%)         | 26 (15%)        |         |
| Lymphovascular invasion| 0 (0%)    | 0 (0%)           | 0 (0%)          | p = 1.000 |
| Yes                  | 394 (85%)     | 250 (84%)        | 144 (85%)       |         |
| No                   | 72 (15%)      | 46 (16%)         | 26 (15%)        |         |
| Neoadjuvant ADT      |               |                  |                 |         |
| Yes                  | 90 (19%)      | 46 (16%)         | 44 (26%)        | p = 0.007 |
| No                   | 376 (81%)     | 250 (84%)        | 126 (74%)       |         |
| Duration of ADT [months] | 3.0 (3.0–3.0)| 3.0 (3.0–3.0) | 3.0 (1.0–3.0) | p = 0.684 |

When considering only patients with UIR PCa, there was a 3% increase in CIR per month of management delay [UHR = 1.03 (95% CI: 1.02–1.04); p < 0.001]. In multivariate modeling, there was a 1% increase in CIR per month of management delay [MHR = 1.01 (95% CI: 1.00–1.03); p = 0.044]. When considering only patients with FIR PCa there was no statistically significant association found between wait time and CIR on univariate [UHR = 1.02 (0.99–1.06); p = 0.250] or multivariate [MHR = 1.02 (0.97–1.07); p = 0.550] analyses.

Table 2
Dosimetry at the time of LDR-BT for the entire cohort and for those with favorable (FIR) and unfavorable (UIR) intermediate-risk prostate cancer. Values given are number (%) or median (inter-quartile-range) as appropriate.

|                      | All Patients | FIR PCa N = 296 | UIR PCa N = 170 | p-value |
|----------------------|--------------|------------------|-----------------|---------|
| Activity [Gy]        | 0.437        | 0.437            | 0.437           | p = -    |
| Number of Needles    | 28 (26–30)   | 28 (26–30)       | 28 (26–30)      | 0.452   |
| Number of Seeds      | 75 (67–84)   | 74 (67–84)       | 76 (68–85)      | 0.389   |
| Gland                | 34.3         | 34.4             | 34.1            | p = -    |
| Volume [cc]          | (28.3–41.1)  | (28.9–40.9)      | (27.2–41.2)     | 0.487   |
| Prostate             | 189.9        | 190.1            | 189.4           | 0.324   |
| D90 [Gy]             | (184.9–193.6)| (184.9–193.9)    | (184.9–193.2)   |         |
| CTV V100             | 98.6         | 98.6             | 98.6            |         |
| [%]                  | (97.8–99.3)  | (97.8–99.3)      | (98.0–99.3)     | 0.625   |
| CTV V150             | 77.8         | 77.9             | 77.6            |         |
| [%]                  | (75.6–79.8)  | (75.7–79.1)      | (75.6–79.1)     | 0.122   |
| CTV V200             | 44.4         | 44.4             | 44.6            | p = -    |
| [%]                  | (40.8–47.5)  | (40.5–47.5)      | (41.5–47.7)     | 0.316   |
| V150 [%]             | (0.00–0.60)  | (0.00–0.60)      | (0.00–0.58)     | 0.304   |
| Rectal V100 [cc]     | (0.00–0.15)  | (0.00–0.15)      | (0.00–0.17)     | 0.401   |

Fig. 1. Cumulative incidence of recurrence and competing risk of non-prostate cancer death for all patients with intermediate risk prostate cancer and treated with LDR-BT. The number of patients at risk is shown at the bottom of the figure.

Fig. 2 shows the CIM for the Cohort. The estimated cumulative incidence of metastases at 60 and 120 months were 4.9% (IQR: 4.9–4.9) and 6.0% (IQR: 5.9–6.0) respectively. Amongst all patients, increased wait times for LDR-BT were found to be associated with an increased cumulative incidence of metastases (CIM) in both univariate and multivariate models. In univariate modeling, there was a 4% increase in the CIM per month of delay in LDR-BT [UHR = 1.04 (1.03–1.06); p < 0.001]. In multivariate modeling, there was a 3% increase in the CIM per month of delay in LDR-BT [MHR = 1.03 (1.02–1.05); p < 0.001]. When considering only patients with UIR PCa there was a statistically significant association between wait time and CIM in both univariate [UHR = 1.05 (95% CI: 1.04–1.06); p < 0.001] and multivariate
When considering only patients with FIR PCa there was no statistically significant association found between wait time and CIM in either univariate [MHR = 1.01 (95% CI: 0.96–1.06); p = 0.013] or multivariate [MHR = 0.96 (0.91–1.01); p = 0.126] analyses. When considering only patients with FIR PCa treated with LDR-BT, the number of patients at risk is shown at the bottom of the figure.

The results of this study are in keeping with those reported by Nam et al for surgical patients in Ontario, Canada. Specifically, they found those patients undergoing radical prostatectomy for prostate cancer and having wait times > 3 months had a 13% decrease in biochemical control when compared to those with shorter wait times [7]. In another study, O’Brien et al found 6 months delays were associated with biochemical progression and surgical upstaging [10]. The two studies that contest these results review experiences where patient wait times were more reasonable (<3 months median) or had shorter follow-up [12,24]. The present study is unique in that it reports on extensive wait times and is focussed only on patients with intermediate risk disease seeking ablative local treatment. This avoids a possible confounder from including patients whom declined active surveillance for relatively indolent disease [25]. However, it does not differentiate patients with FIR PCa who may be eligible for further disease monitoring [26].

The findings of this study are important given the increased incidence of prostate cancer that is projected moving forward and the potential for a surge in new prostate cancer diagnoses after COVID-19 [2,19,20]. Without careful attention to radiotherapy and surgical resource planning, other centers may find expansions of their own waitlists. Despite this, increasing burden of disease may require thoughtful consideration and implementation of appropriate alternatives that are acceptable to patients. In the study center’s anecdotal experience, the primary reason for patients remaining on the LDR-BT waitlist was a lack of acceptable treatment alternatives rather than patient preferences for a delay in treatment. Patients consenting to brachytherapy were often not candidates for radical prostatectomy and for the majority of the study period, the comparable external beam radiotherapy alternative consisted of 78 Gy in 39 daily treatments using 3D conformal radiotherapy planning which presented an alternative with significantly higher risks of gastrointestinal toxicity. Within the study center, to help address the ongoing issues with prostate brachytherapy waitlists the department has introduced a 5 fraction, fiducial guided prostate SBRT program [21–23]. This is in addition to ongoing advocacy initiatives looking to increase the operating room resources allocated to the prostate brachytherapy program.

This study was subject to several limitations from its retrospective design. Importantly, routine post-implant dosimetry was not calculated on the post-treatment CT images. This may have led to some patients not being allocated to the prostate brachytherapy program [21–23]. This is in addition to ongoing advocacy initiatives looking to increase the operating room resources allocated to the prostate brachytherapy program.

Fig. 2. Cumulative incidence of metastatic disease and competing risk of non-prostate cancer death for all patients with intermediate risk prostate cancer and treated with LDR-BT. The number of patients at risk is shown at the bottom of the figure.

Fig. 3. Kaplan-Meier estimated overall survival for all patients with intermediate risk prostate cancer and treated with LDR-BT. The number of patients at risk is shown at the bottom of the figure.
applicable. Additionally, re-staging procedures such as repeat biopsy, repeat digital rectal examination or multiparametric magnetic resonance imaging were not routinely recommended for patients on the waitlist to receive LDR-BT and therefore were not collected for the purposes of this study. Hence it is difficult to determine if there is a discernable clinical upstaging that is directly responsible for the outcomes within this study. However, patients were monitored using PSA blood testing every 2–4 months and over the study period it was common practice to offer external beam radiotherapy to patients with biochemical upstaging. Anecdotally, many patients refused a change in management strategy. These conversations were not recorded reliably enough to meet the scientific standard for inclusion in this study. Finally, although it is the experience of managing physicians at the study center that patients remained on waitlists primarily due to resource constraints that prevented more timely delivery of LDR-BT, the retrospective nature of this study limits the strength of this conclusion. It is possible that other factors such as personal patient preferences for delaying therapy may have contributed to excessive wait times. However, even if this were the case, it is unlikely to have biased the results of this study, as this would required patients with more adverse risk to preferentially opt for a greater delay in treatment, which would not be expected to be the case. Larger multi-center studies would be warranted to more conclusively determine the effect of prolonged wait times on patient outcomes. However, it is likely unethical to impose a deliberate delay in patient treatments for the purposes of such a study.

In conclusion, this study found that increases in wait times for LDR-BT were associated with an increased risk of recurrence and metastases in patients with intermediate-risk PCs. Extensive wait times were a result of resource limitations in the local healthcare system and the results of this study should be considered when planning future resource allocation for genitourinary malignancies in single-payer healthcare systems.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This project was supported in part by funding from the University of Calgary and the Alberta Cancer Foundation.

Author Contributions

R.A.K. and K.M. collected and analyzed data and wrote the manuscript. H.Q., K.T., M.S., M.R., S.H., P.G., and T.M. provided scientific input and assisted with manuscript preparation. K.M. designed the study and supervised the project.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ctro.2021.06.008.

References

[1] Canadian Cancer Society/National Cancer Institute of Canada. Canadian Cancer Statistics 2005. Can Cancer Soc 2005:1–110.
[2] Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int 2011;108:1734–8.
[3] Roehrborn CG, Black JK. The economic burden of prostate cancer. BJU Int 2011; 108:806–13.
[4] Krahn MD, Brenner KE, Luo J, Alibhai SMH. Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events. Curr Oncol 2014;21:457–65.
[5] Jemal A, Ma J, Siegel R, et al. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol 2016;2:1657–60.
[6] Jemal A, Culp MB, Ma J, et al. Prostate cancer incidence 5 years after US Preventive Services Task Force Recommendations against screening. J Natl Cancer Inst 2012;104:654–71.
[7] Nam RK, Jewett MAS, Krahn MD, et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol 2002;10:1891–8.
[8] Zakaria AS, Couture F, Nguyen DD, et al. Impact of surgical wait times during summer months on the oncological outcomes following robotic-assisted radical prostatectomy: 10 years’ experience from a large Canadian academic center. World J Urol 2020.
[9] Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117: 5039–46.
[10] O’Brien D, Loeb S. Carvalhal GF, McGuire BB, Kan D, Hofer MD, et al. Delay of surgery in men with low risk prostate cancer. J Urol 2011;185:2143–7.
[11] Westerman ME, Sharma V, Bailey GC, Boorjian SA, Frank I, Gettman MT, et al. Impact of time from biopsy to surgery on complications, functional and oncologic outcomes following radical prostatectomy. Int Braz J Urol 2019;45:648–77.
[12] Fossati N, Rossi MS, Cucchiara V, Gandaglia G, Dell’Oglio P, Moschini M, et al. Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely? Urol Oncol Semin Orig Invest 2017;95:150.e5–150.e15.
[13] Mohler J, Antonarakis E, Armstron A, et al. NCCN clinical practice guidelines in oncology - prostate cancer. NCCN Clin Pract Guidel Oncol Version 2019;1:2019.
[14] Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016;69:428–35.
[15] Peacock M, Martell K, Taggar A, Meyer T, Smith W, Sia M, et al. Institutional long-term outcomes at the first Canadian center performing intraoperatively planned low-dose-rate brachytherapy alone in low- and intermediate-risk prostate cancer. Brachytherapy 2017;16:822–30.
[16] Rose JN, Crook JM, Pickles T, Keyes M, Morris WJ. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity. Brachytherapy 2015;14:342–9.
[17] Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965–74.
[18] Fine JP, Gray RJ, Fine JP, et al. A proportional hazards model for the subdistribution of a competing risk: stable URL: http://www.jstor.org/stable/2670170 All use subject to http://about.jstor.org/terms. J Am Stat Assoc 1999;94: 496–509.
[19] London JW, Fazio-Eymullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clin Cancer Informatics 2020;4(1):657–65. https://doi.org/10.1200/JCOI.20.00068.
[20] Maniere C, Spicer J, Morris M, Purushotham A, Noble E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delay in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020;21 (8):1023–34.
[21] Widmark A, Gunlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HOYO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 2019;394(10196):385–95.
[22] Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20(11): 1531–43.
[23] Jackson WC, Silva J, Hartman HE, Dens RT, Kishan AU, Beeler WH, et al. Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 2019;104(4):778–89.
[24] Graefen M, Witz J, Chun K-H, F. Schollm T, Haese A, Huland H. Reasonable delay of surgical treatment in men with localized prostate cancer - Impact on prognosis? Eur Urol 2005;47(6):756–60.
[25] Kloot L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Urol Oncol 2010;28(3):126–31.
[26] Kloot L. Active surveillance for intermediate risk prostate cancer. Curr Urol Rep 2017;18:80.